Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000411466 | SCV000486237 | likely pathogenic | GNE myopathy | 2016-04-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001861380 | SCV002282100 | likely pathogenic | GNE myopathy; Sialuria | 2024-01-13 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 539 of the GNE protein (p.Leu539Ser). This variant is present in population databases (no rsID available, gnomAD 0.007%). This missense change has been observed in individuals with distal myopathy (PMID: 21307865, 30390020). This variant is also known as p.L508S. ClinVar contains an entry for this variant (Variation ID: 370826). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on GNE protein function. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Mayo Clinic Laboratories, |
RCV003480623 | SCV004226608 | pathogenic | not provided | 2022-05-18 | criteria provided, single submitter | clinical testing | PP3, PM2, PM3_strong, PS4 |